Antibody-drug conjugates

Antibody-drug conjugates (ADCs) represent a promising class of anti-cancer therapeutics with significant therapeutic potential.

This innovative approach combines the targeting specificity of mAbs with the potent cytotoxicity of chemotherapeutic agents, offering improved efficacy and reduced systemic side effects compared to conventional chemotherapy.

Mabqi’s LiteMab Antibody Discovery Studio is well suited to support ADC discovery campaigns.

The company benefits from a strong track record through partnered programs and discovery campaigns:

Fully human antibody display libraries to generate native antibodies or pH-sensitive antibodies
AI-powered Dual technology platform (Phage-yeast display): selection process optimized for rapid identification of best clones
Hits screening: hits characterization and screening. If initially requested, of pH-sensitive characteristic is confirmed (in vitro binding and kinetics)
Hits validation: functional assays such as internalization assays, epitope binning, in vitro cytotoxicity on target expressing cells, other assays on-demand.

Why choose LiteMab© Antibody Discovery Studio?

Versatile target compatibility: Excels with any targets from soluble to membrane proteins

Tumor-selective binders: thanks to the LiteMab© Sense platform, we generate tumor-selective binders to enhance specificity, PK, and reduce off-target effects

Plug & Play format: scFv format enables rapid assembly and flexible combination of binding domains, significantly streamlining the design and optimization of antibody drug conjugates

Reliable, high-throughput discovery worlkflow: Our streamlined antibody discovery workflow enables rapid delivery of high‑quality, fully human binders. From target to validated lead, we combine robust selection, in‑depth characterization, and functional validation into a single, efficient process tailored for complex biologics like antibody drug conjugates.

Track-record

Mabqi successfully completed its first ADC out-licensing deal.

The company announced in 2026 the exercise of an option under its research collaboration agreement for a jointly discovered antibody-drug conjugate (ADC), subsequently acquired by a leading pharmaceutical company.

This transaction underscores the strategic value of LiteMab Antibody Discovery platform in advancing oncology therapeutics.

Full press release available here.

Feel free to reach out to learn more on our expertise for ADC programs.

Expand your pipeline with next-gen drug candidates!

Curious to explore your challenges with a specialized discovery partner?
Let’s connect!